

Wize Pharma appoints Joseph Tauber on Scientific Advisory Board

16 March 2018 | News

Dr. Tauber is an internationally recognized authority in the field of ocular surface diseases, including DES and meibomitis management



Wize Pharma, Inc., a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders. It has appointed Dr. Joseph Tauber on Company's Scientific Advisory Board.

Dr. Tauber is an internationally recognized authority in the field of ocular surface diseases, including DES and meibomitis management.

He has been a Principal Investigator in various clinical research programs, including those that led to the approval of the only two medications approved by the FDA for the treatment of DES - Restasis® and Xiidra®.

Since last three decades devoted to research, Dr. Tauber has been a principal investigator in over 125 research studies of high-risk corneal transplantation, inflammation and allergic eye diseases, corneal infectious diseases and numerous studies related to DES.

He has written five book chapters and over 60 articles in ophthalmology medical journals. He has been awarded the Heed Ophthalmic Foundation Fellowship Award and the National Eye Institute Individual NRSA Award.

Dr. Tauber received his doctorate from Harvard Medical School, his training in internal medicine at Beth Israel Hospital and in ophthalmology at Tufts-New England Medical Center.

He has served as Clinical Professor of Ophthalmology at Kansas University School of Medicine and University of Missouri-Kansas City School of Medicine.

A board-certified ophthalmologist, Dr. Tauber is the Founder of Tauber Eye Center in Kansas City, Missouri.